Benzinga | Jan 27, 2022 07:38AM EST

BridgeBio Pharma Announces Dosing Of First Patient In Phase 1/2 Trial Of Investigational Gene Therapy For Congenital Adrenal Hyperplasia

- If successful, BridgeBio's investigational gene therapy BBP-631 would be the first therapy for CAH to restore the body's hormone and steroid balance by enabling people with CAH to make their own cortisol and aldosterone



-Initial Phase 1/2 data readout anticipated in the second half of 2022

-BridgeBio's gene therapy portfolio also includes a clinical stage program for Canavan disease and preclinical programs for classic galactosemia, TMC1 hearing loss, tuberous sclerosis types 1 and 2, cystinuria and a genetic dilated cardiomyopathy